{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:05:06Z","timestamp":1790103906889,"version":"4.0.1"},"reference-count":28,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"\n Objectives<\/jats:title>\n To assess differential changes in prescribing uptake of dapagliflozin and empagliflozin relative to canagliflozin in England following the July 2023 expansion of heart failure guideline recommendations.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Controlled interrupted time series (ITS) analysis using segmented regression with Newey-West SEs and month fixed effects to account for seasonality.<\/jats:p>\n <\/jats:sec>\n \n Setting and participants<\/jats:title>\n National monthly primary care prescribing data in England (January 2019\u2013December 2025). Aggregate prescribing data were analysed at the drug level.<\/jats:p>\n <\/jats:sec>\n \n Primary and secondary outcome measures<\/jats:title>\n Primary outcome: monthly utilisation measured in defined daily doses (DDDs). Secondary outcomes: monthly prescription items, market share of total SGLT2 inhibitor DDDs and net ingredient cost (NIC).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall utilisation increased for all three monotherapy SGLT2 inhibitors, but prescribing trajectories diverged markedly following the intervention. Dapagliflozin\u2019s market share rose from 33.2% to 55.9%, while empagliflozin declined to 41.0% and canagliflozin to 3.1%. The controlled ITS model showed no immediate step change at July 2023. However, dapagliflozin demonstrated a significant differential postintervention slope increase relative to canagliflozin (\u03b2=0.042, 95% CI 0.035 to 0.049; p<0.001), corresponding to an additional 4.3% monthly growth. Empagliflozin showed a smaller but significant relative increase (\u03b2=0.015, 95% CI 0.008 to 0.022; p<0.001). Counterfactual analysis estimated 68.4 million excess dapagliflozin DDDs and 21.2 million excess empagliflozin DDDs over the postintervention period. Results were consistent across prespecified breakpoint and formulation sensitivity analyses; however, an exploratory NIC-adjusted analysis attenuated the dapagliflozin differential slope by 33%, indicating sensitivity to concurrent price changes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n SGLT2 inhibitor uptake in English primary care has been highly heterogeneous. The marked acceleration in dapagliflozin prescribing from July 2023, against stable background trends for canagliflozin, is temporally consistent with expanded heart failure guideline recommendations. However, several important limitations preclude definitive causal attribution. First, because this study analysed aggregate prescribing data without patient-level indications, we cannot directly attribute observed changes to heart failure rather than to diabetes, chronic kidney disease or other factors. Second, the substantial concurrent reduction in dapagliflozin\u2019s NIC (from \u00a31.38 to \u00a30.35 per DDD) represents a competing explanation; exploratory adjustment for NIC attenuated the dapagliflozin estimate by approximately one-third, though this magnitude cannot be interpreted as a causal attribution because NIC may be endogenous. The observation that empagliflozin, which experienced a more modest price change, showed a smaller differential effect is hypothesis-generating and requires confirmation with methods that can separate guideline from price effects. Third, the ecological design inherently limits causal inference. These findings highlight that class-wide guideline updates do not translate into uniform prescribing and underscore the importance of monitoring drug-specific adoption patterns while considering the complex interplay of clinical, economic and policy factors.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-122364","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:35:50Z","timestamp":1790102150000},"page":"e122364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-3469","authenticated-orcid":false,"given":"Mohammed Ibrahim","family":"Aladul","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-2297","authenticated-orcid":false,"given":"Rima A.","family":"Hijazeen","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab M.","family":"Al-Shammaa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026092211354326000_16.9.e122364.1","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/jdi.70187","article-title":"A decade of SGLT2 inhibitors: Lessons learned and the road ahead in type 2 diabetes","volume":"16","author":"Kimura","year":"2025","journal-title":"J Diabetes Investig"},{"key":"2026092211354326000_16.9.e122364.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2026092211354326000_16.9.e122364.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2026092211354326000_16.9.e122364.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"2026092211354326000_16.9.e122364.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2026092211354326000_16.9.e122364.6","unstructured":"National Institute for Health and Care Excellence . Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (technology appraisal TA902). London: NICE; 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ta902 [Accessed 4 Apr 2026]."},{"key":"2026092211354326000_16.9.e122364.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-04194-9","article-title":"A conceptual model of factors potentially influencing prescribing decisions for chronic conditions: an overview of systematic reviews","volume":"23","author":"Gittus","year":"2025","journal-title":"BMC Med"},{"key":"2026092211354326000_16.9.e122364.8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.sapharm.2019.06.018","article-title":"Factors influencing the implementation of clinical pharmacy services for hospitalized patients: A mixed-methods systematic review","volume":"16","author":"Onozato","year":"2020","journal-title":"Res Social Adm Pharm"},{"key":"2026092211354326000_16.9.e122364.9","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-7-50"},{"key":"2026092211354326000_16.9.e122364.10","unstructured":"National Institute for Health and Care Excellence . Canagliflozin for treating type 2 diabetes (technology appraisal TA288). London: NICE; 2013. Available: https:\/\/www.nice.org.uk\/guidance\/ta288 [Accessed 10 Apr 2026]."},{"key":"2026092211354326000_16.9.e122364.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2750","article-title":"Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis","volume":"350","author":"Kontopantelis","year":"2015","journal-title":"BMJ"},{"key":"2026092211354326000_16.9.e122364.12","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw098"},{"key":"2026092211354326000_16.9.e122364.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"2026092211354326000_16.9.e122364.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2026092211354326000_16.9.e122364.15","unstructured":"National Institute for Health and Care Excellence . Empagliflozin for treating chronic heart failure with reduced ejection fraction. London: NICE; 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ta773 [Accessed 12 Apr 2026]."},{"key":"2026092211354326000_16.9.e122364.16","unstructured":"National Institute for Health and Care Excellence . Canagliflozin for treating chronic kidney disease in people with type 2 diabetes. single technology appraisal. London: NICE; 2020. Available: https:\/\/www.nice.org.uk\/guidance\/gid-ta10555\/documents\/scope-consultation-comments-and-responses [Accessed 20 Mar 2026]."},{"key":"2026092211354326000_16.9.e122364.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"2026092211354326000_16.9.e122364.18","unstructured":"NHS Business Services Authority . Prescription cost analysis (PCA) monthly administrative data. London: NHS; 2026. Available: https:\/\/opendata.nhsbsa.net\/dataset\/prescription-cost-analysis-pca-monthly-data [Accessed 1 Apr 2026]."},{"key":"2026092211354326000_16.9.e122364.19","unstructured":"OpenPrescribing . Explore England\u2019s prescribing data. London: NHS; 2026. Available: https:\/\/openprescribing.net\/ [Accessed 1 Apr 2026]."},{"key":"2026092211354326000_16.9.e122364.20","unstructured":"National Institute for Health and Care Excellence . British national formulary. London: BMJ Group and Pharmaceutical Press; 2025. Available: https:\/\/bnf.nice.org.uk"},{"key":"2026092211354326000_16.9.e122364.21","unstructured":"World Health Organization collaborating centre for drug statistics methodology. ATC\/DDD Index Oslo: WHOCC; 2025. Available: https:\/\/www.whocc.no\/atc_ddd_index"},{"key":"2026092211354326000_16.9.e122364.22","doi-asserted-by":"publisher","DOI":"10.3310\/hta8060"},{"key":"2026092211354326000_16.9.e122364.23","doi-asserted-by":"publisher","DOI":"10.2307\/2297912"},{"key":"2026092211354326000_16.9.e122364.24","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500208"},{"key":"2026092211354326000_16.9.e122364.25","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"2026092211354326000_16.9.e122364.26","unstructured":"Health Research Authority . Does my study need research ethics committee review? London: HRA; 2023. Available: https:\/\/www.hra.nhs.uk"},{"key":"2026092211354326000_16.9.e122364.27","first-page":"1401","article-title":"Interactions between physicians and the pharmaceutical industry: what does the literature say?","volume":"149","author":"Lexchin","year":"1993","journal-title":"CMAJ"},{"key":"2026092211354326000_16.9.e122364.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12961-020-00611-y","article-title":"Health technology assessment of biosimilars worldwide: a scoping review","volume":"18","author":"Ascef","year":"2020","journal-title":"Health Res Policy Syst"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-122364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:35:54Z","timestamp":1790102154000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-122364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,22]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-122364"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-122364","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}